APH

ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (the "Company" or
"ALDA") has filed its patent application, "Antiseptic Compositions for the
Treatment of Infections", with the US Patent and Trademark Office (Serial
#12/933,358). The application, first submitted to the Canadian Intellectual
Property office for review in March, 2008 under the Patent Cooperation Treaty,
seeks protection for the composition and preparation of T36(R) formulations that
also contain steroids, anesthetics or analgesics for use on topical infections
and, in particular, inflamed infections. Typically, infections with associated
inflammation are treated with separate antiseptic and anti-inflammatory
preparations. The new T36(R) formulations combine these properties into a single
treatment, making the prescription process easier for the physician and the
application easier for the patient. Submissions to the European and Canadian
patent offices are also planned. This patent is the third in a series of patents
providing protection for the T36(R) technology that have been issued or are
pending. 


The first patent, providing protection for the composition and production
methods for ALDA's T36(R) formulation until August 20, 2022, is:




--  issued in Australia (#2002322916), the US (#7,338,927) and China
    (#ZL02829642.7), 
--  allowed and pending in Canada (Patent Application #2,495,938) and 
--  pending in the EU (Patent Application #02754054.1-2113). 



The second patent, providing protection for the use of T36(R) as a component of
a personal lubricant, in a method of preventing or reducing the transmission of
a sexually transmitted diseases including Herpes, Chlamydia and HIV and for use
in sanitizers and cleansers in creams, ointments and wipes until August 20,
2022, is:




--  issued in Australia (#2007237333) and the US (#7,560,422), 
--  allowed and is pending in Canada (Patent Application #2,495,938) and 
--  pending in China (Chinese Divisional Patent Application #200710142798.3)
    and the EU (Patent Application #02754054.1-2113). 



According to Dr. Terrance Owen, President & CEO, "Intellectual property
protection is one of the key assets of emerging pharmaceutical companies. We are
committed to building the Company's patent portfolio so that we have the
protection required in the main international markets that we are targeting with
the therapeutic products derived from the T36(R) technology."


About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived
from its patented T36(R) technology. The company trades on the TSX Venture
Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The
Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and
the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the
Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian
Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant
cleaning products. The Company was also selected as one of the TSX Venture 50
companies in the Technology and Life Sciences sector for 2010.


Terrance G. Owen, Ph.D., MBA, President & CEO 

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press
release that involves ALDA's expectations, plans, intentions or strategies
regarding the future are forward-looking statements that are not facts and
involve a number of risks and uncertainties. ALDA generally uses words such as
"outlook", "will", "could", "would", "might", "remains", "to be", "plans",
"believes", "may", "expects", "intends", "anticipates", "estimate", "future",
"plan", "positioned", "potential", "project", "remain", "scheduled", "set to",
"subject to", "upcoming", and similar expressions to help identify
forward-looking statements. The forward-looking statements in this release are
based upon information available to ALDA as of the date of this release, and
ALDA assumes no obligation to update any such forward-looking statements.
Forward-looking statements believed to be true when made may ultimately prove to
be incorrect. These statements are not guarantees of the future performance of
ALDA and are subject to risks, uncertainties and other factors, some of which
are beyond its control and may cause actual results to differ materially from
current expectations.

Grafico Azioni Aphria Inc. (TSXV:APH)
Storico
Da Apr 2024 a Mag 2024

Grafico Azioni Aphria Inc. (TSXV:APH)
Storico
Da Mag 2023 a Mag 2024